Worth reading
37Immaterial
Scored from 4 of 5 sectionsDirection
Improvement
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Avoiding a definitive answer
How definitive the wording is.Agreements reached under this partnership
Business Alliance3750ADR Biomedical Holdings Inc.
Alliance partnerNorthern Farm
Details of the alliance
- 1
Applied research on Neocella (NeoCella) in the field of racehorse breeding
- 2
Accumulation of cases, confirmation of safety, and verification of reproducibility
These are items that the documents state the two companies will work on. The lines above and below represent arrangements between the two companies.
Impact on Business Performance
The impact of this matter on results for the fiscal year ending March 2027 is currently expected to be immaterial.
Alliance start dateSequentially from July 2026 onward (planned)
| Item | Details |
|---|---|
| Name of alliance partner | Northern Farm |
| Type of alliance | Business Alliance |
| Details of the alliance | Applied research on Neocella (NeoCella) in the field of racehorse breeding, Accumulation of cases, confirmation of safety, and verification of reproducibility |
| Alliance start date | Sequentially from July 2026 onward (planned) |
| Impact on Business Performance | The impact of this matter on results for the fiscal year ending March 2027 is currently expected to be immaterial. |
Items this document does not state (18)
Alliance partner's business activitiesAlliance partner's locationAlliance partner's capitalAlliance partner's net salesAlliance partner's operating incomeNumber of shares acquiredAcquisition priceShareholding ratioOverview of the joint ventureOwnership ratioDispatch of directors and officersContract PeriodNumerical targets under the allianceShareholding PolicyDate of board resolutionContract DateShare Acquisition Date and Payment DateChange in major shareholders
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.No significant safety issues have been identified to date in NeoCella's quality and nonclinical testing, and pregnancies have been confirmed through joint research with Northern Farm.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.